Why the study?
Do thrombolytic agents (tenecteplase, alteplase, reteplase) reduce platelet aggregation in blood from patients with coronary disease and healthy subjects?
Population
Blood from 11 patients with coronary disease and 5 healthy subjects (n=16)
Comparison
Incubation for 30 min with tenecteplase… vs Control buffer
Design
Preclinical
Follow-up
30 min
Authors
Loading...
Alteplase shows greater ex vivo antiplatelet effects than tenecteplase or reteplase; leaves open clinical relevance in acute coronary syndromes.
Do thrombolytic agents (tenecteplase, alteplase, reteplase) reduce platelet aggregation in blood from patients with coronary disease and healthy subjects?
Alteplase demonstrates direct antiplatelet effects independent of GP IIb/IIIa and P-selectin expression, which may be relevant for reperfusion in acute myocardial infarction.
Gurbel et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: